$VRSN

VeriSign, Inc. Q2 2026 Earnings Call Summary

VeriSign reported Q2 2026 updates including 12.7 million record new domain registrations, driven by AI-enabled tools and registrar marketing. 2026 domain base growth guidance was raised and narrowed to 5.2% to 6.0%. The board authorized $884 million more share repurchases. VeriSign also outlined .web delegation, pricing flexibility, and a $0.81 per-share quarterly dividend starting Aug 2026.

Original reporting
Published Jul 25, 2026, 2:45 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 25, 2026, 2:48 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
VeriSign, Inc. Q2 2026 Earnings Call Summary — source image
Decision brief

The 30-second read

$VRSNBullishMed
01

Why it matters

Traders can update models using the raised 2026 domain base growth guidance range, the incremental $884M buyback authorization, and the stated revenue recognition split tied to the November 2026 .com price increase.

02

Market read

The combination of updated growth guidance, expanded repurchases, and specific .web/.com monetization timelines provides actionable inputs for near-term positioning and risk management.

03

What to watch

CapEx pressure from server memory and data center components could constrain margins, and the article does not quantify how much AI tailwinds persist beyond the current momentum window.

Relevance 7/10Novelty 7/10Timing: post-earnings call, ahead of late-2026/early-2027 .web general availability and August 2026 dividend payment

Background

This is a summary of VeriSign’s Q2 2026 earnings call, focusing on domain registration growth drivers, the .web TLD delegation and launch plan, and capital return.

Company-level read

Ticker impact

$VRSNBullishMedium confidence
Context

VeriSign raised and narrowed 2026 domain base growth guidance to 5.2% to 6.0% and authorized an additional $884M share repurchase.

Expected impact

Moderately positive bias into the next earnings cycle as traders price in higher growth and capital return, with volatility around .web rollout timing.

Evidence & confidence

The article provides specific, decision-relevant datapoints: updated 2026 guidance range, $884M incremental buyback authorization, and concrete .web launch milestones plus .com price-change revenue recognition timing.

Market effects

Reinforces the narrative that AI-driven demand is lifting domain registrations and that new TLDs can expand pricing flexibility versus regulated .com/.net.

Highlights stronger growth in the U.S. and EMEA, which may influence regional registrar and DNS-related demand expectations.

DNS governance stability under ICANN and .web delegation could affect global expectations for TLD monetization and security product adoption.

Counterpoint

The guidance and buyback may be offset by execution risk around .web launch security testing, trademark sunrise, and potential registration pull-forward effects from the November .com price increase.

Key entities

  • VeriSign, Inc.

    DNS and domain registry operator; subject of the earnings call summary with guidance, buyback, dividend, and .web launch details.

Related articles

$VRSNMedAI 8/10

VeriSign Q2 Earnings Call Highlights

VeriSign reported Q2 cash of $1.034B and updated 2026 guidance. Management raised and narrowed domain name base growth to 5.2% to 6%. Full-year outlook: revenue $1.745B-$1.755B, operating income $1.185B-$1.195B. Board increased buyback authorization to $1.5B and declared a $0.81 dividend. VeriSign said .web was delegated into the DNS root zone.

$VRSNHigh

VERISIGN INC/CA (VRSN): Results of Operations and Financial Condition

VERISIGN INC/CA (VRSN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 q22026earningsrelease.htm EX-99.1 Document Verisign Reports Second Quarter 2026 Results RESTON, VA - July 23, 2026 - VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today reported financial results

$DRIMedAI 8/10

DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment

DRI Healthcare Trust (TSX: DHT.UN, DHT.U) reported Q2 2026 results for the quarter ended June 30, 2026: total income $50.1M, total cash receipts $46.5M, and adjusted EBITDA $42.6M. It repurchased 89,513 units at $11.65 and paid a $0.11/unit distribution. After quarter-end, it exercised a put option on Ekterly for about $178M and received FDA approval for Lumvoa (veligrotug), triggering $75M milestone payments.

$LGNDMed

Ligand Pharmaceuticals Incorporated Q2 2026 Earnings Call Summary

Ligand Pharmaceuticals reported Q2 2026 results and discussed its XOMA Royalty acquisition, adding 120+ assets and extending cash flow duration through 2040. Management cited 32% YoY royalty revenue growth and expects 2026 royalty revenue of $225M-$250M with cash opex halved since 2022. Ligand issued a $700M zero-coupon convertible, raised 2026 adjusted EPS guidance to $9.00-$9.50, and expects accretion from XOMA in 2H26 and 2027.

$KDPMed

Keurig Dr Pepper Inc. Q2 2026 Earnings Call Summary

Keurig Dr Pepper reported Q2 2026 results that exceeded expectations, citing double-digit U.S. Refreshment Beverages growth and day-one integration of JDE Peet's. Dr Pepper Zero Sugar grew 30% in retail sales and energy reached 9% market share. U.S. Coffee faced margin pressure from hedging and tariffs. KDP reaffirmed low double-digit EPS growth for 2026 and low-double-digit legacy growth at the high end of 4% to 6%.